HC Wainwright Lowers Earnings Estimates for Nuvectis Pharma

Nuvectis Pharma, Inc. (NASDAQ:NVCT) – Analysts at HC Wainwright decreased their FY2026 earnings per share estimates for Nuvectis Pharma in a research report issued on Wednesday, November 4th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings of ($1.91) per share for the year, down from their previous forecast of ($1.02). HC Wainwright currently has a “Buy” rating and a $39.00 target price on the stock. The consensus estimate for Nuvectis Pharma’s current full-year earnings is ($1.01) per share. HC Wainwright also issued estimates for Nuvectis Pharma’s Q4 2026 earnings at ($0.27) EPS, FY2027 earnings at ($1.97) EPS and FY2028 earnings at ($2.35) EPS.

A number of other equities research analysts have also issued reports on NVCT. Loop Capital set a $40.00 price objective on shares of Nuvectis Pharma in a report on Tuesday, September 1st. Cantor Fitzgerald started coverage on shares of Nuvectis Pharma in a report on Monday, August 24th. They issued an “overweight” rating on the stock. Lucid Cap Mkts upgraded shares of Nuvectis Pharma to a “strong-buy” rating in a research report on Tuesday, September 1st. Finally, Weiss Ratings upgraded shares of Nuvectis Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, September 21st. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Nuvectis Pharma presently has a consensus rating of “Moderate Buy” and a consensus target price of $36.25.

Nuvectis Pharma Trading Down 3.8%

Shares of NVCT opened at $17.76 on Friday. The business’s 50 day moving average is $20.98 and its 200 day moving average is $14.81. Nuvectis Pharma has a 12-month low of $5.55 and a 12-month high of $29.27. The company has a market capitalization of $579.76 million, a PE ratio of -9.40 and a beta of -0.21.

Nuvectis Pharma (NASDAQ:NVCT) last released its quarterly earnings data on Wednesday, November 4th. The company reported ($1.02) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.78).

Hedge Funds Weigh In On Nuvectis Pharma

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in NVCT. Oppenheimer & Co. Inc. increased its stake in Nuvectis Pharma by 17.3% in the 3rd quarter. Oppenheimer & Co. Inc. now owns 86,291 shares of the company’s stock worth $1,822,000 after acquiring an additional 12,725 shares during the last quarter. Iridian Asset Management LLC CT boosted its position in shares of Nuvectis Pharma by 2.1% during the 3rd quarter. Iridian Asset Management LLC CT now owns 793,207 shares of the company’s stock valued at $16,753,000 after acquiring an additional 16,129 shares during the last quarter. Alyeska Investment Group L.P. bought a new position in shares of Nuvectis Pharma during the 2nd quarter valued at approximately $5,057,000. Stonepine Capital Management LLC bought a new position in shares of Nuvectis Pharma during the 2nd quarter valued at approximately $735,600. Finally, Bank of America Corp DE purchased a new position in shares of Nuvectis Pharma in the second quarter valued at $218,000. 96.77% of the stock is owned by institutional investors.

About Nuvectis Pharma

Nuvectis Pharma, Inc is a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer, with an emphasis on cancers that have limited therapeutic options. The company is headquartered in Fort Lee, New Jersey, and its common stock trades on the Nasdaq Capital Market under the symbol NVCT.

Nuvectis Pharma’s lead product candidate is NXP800, an orally administered small-molecule inhibitor of heat shock protein 90 (HSP90). The company is evaluating NXP800 in clinical studies for certain advanced solid tumors, including platinum-resistant ovarian cancer and cholangiocarcinoma.